Abstract:To achieve targeted, truly systemic therapeutic gene delivery to tumors, we exploited the observation that infection by a retrovirus proceeds initially through a non-specific adsorption stage prior to envelope-receptor recognition/internalization. Antigen specific, primary murine OT-1 T cells can be incubated in vitro with retroviral stocks which adhere to the cell surface. In vitro, virus can be handed off to target cells upon co-culture with the T cells, dependent upon cell contact, envelope/receptor interactions and local heparanase expression as provided by T cell activation upon encounter of antigen (ovalbumin) by the OT-1 T cells. Retroviral particles, pre-adsorbed to the surface of OT-1 T cells in vitro, were available for hand off in vivo to B16ova tumors distant from the site of T cell injection at high enough concentrations for therapeutic levels of gene transfer to occur. We have now delivered a variety of therapeutic genes to tumors, including HSVtk, IL-12 and the chemokine CCL-21. Pre- adsorption of vectors encoding each of these genes has led to therapeutic benefits in terms of direct local cell killing (HSVtk in combination with lymphodepletion), generation of potent immunizing activity (IL-12) and significant enhancement of the efficacy of subsequent doses of adoptively transferred, unmodified T cells (CCL-21). We have also characterized a second pathway by which viral particles expressing no envelope (BALD particles) can be handed off from T cells dependent upon T cell activation. Release of viral particles from the T cell surface coincides with the penetration of perforin-containing cytotoxic vesicles from the antigen activated T cells. The endosomolytic properties of perforin promote release of these viral particles from the endosome and, in situations where direct T cell killing does not occur, the virus goes onto to generate a productive infection. Thus, T cell mediated delivery of MLV core particles can be used to deliver therapeutic retroviral vectors in vivo using targeting at the level of T cell activation, thereby dispensing with the need to target viral envelopes. We have also investigated the possibilities of using antigen specific T cells to deliver replication competent viruses to tumors both in vitro and in vivo. In particular, we have demonstrated that replication competent Vesicular Stomatitis virus expressing GFP can be used to load OT-1 T cells. The virus infects these T cells only at very low levels and does not kill them. However, the T cells produce VSV particles at appreciable levels 48-72 hours post loading suggesting that they may be able to carry the viruses to tumors in vivo and lead to productive infection following intratumoral T cell accumulation. Therefore, the protection, concentration, and targeted delivery of viruses by T cell carriers offers great potential for the delivery of vector stocks into the circulation of patients. By careful selection of the virus, and therapeutic gene that is used, significant synergy can be achieved over the use of virotherapy, or adoptive T cell therapy, alone.

Lentivirus-Mediated Gene Transfer and Expression in Established Human Tumor Antigen-Specific Cytotoxic T Cells and Primary Unstimulated T Cells

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

812. Cellular Delivery of Gene Therapy Vectors

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Progression and Application of HIV-1-derived Lentivectors

Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences

High-titer Lentiviral Vectors Stimulate Fetal Calf Serum-Specific Human CD4 T-cell Responses: Implications in Human Gene Therapy

Potent Gene Transfer in Human Primary T Lymphocytes Using Interleukin-2-displaying Lentiviral Vectors

Analysis of hepatic lentiviral vector transduction; implications for preclinical studies and clinical gene therapy protocols

Analysis of hepatic lentiviral vector transduction; implications on preclinical studies and clinical gene therapy protocols.

Lentiviral Vector Transduction of Hematopoietic Stem Cells That Mediate Long‐Term Reconstitution of Lethally Irradiated Mice

Study on High-efficiency Gene Transfer of Pseudotyped HIV Vector

Specific T-cell Receptor Gene Transfer Enhances Immune Response: A Potential Therapeutic Strategy for the Control of Human Cytomegalovirus Infection in Immunocompromised Patients

High-Efficiency Lentiviral Genetic Modification of Primary Human Natural Killer Cells

Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy.

DNA Transposons for Modification of Human Primary T Lymphocytes.

High‐Level Sustained Transgene Expression in Human Embryonic Stem Cells Using Lentiviral Vectors

Gene delivery into primary cerebral cortical neurons by lentiviral vector.

Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes